Skip to main content

3 Result(s)

within Yoshimasa Shiraishi Remove this filter Medicine & Public Health Remove this filter English Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    Population pharmacokinetic–pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer

    Docetaxel is used to treat many cancers, and neutropenia is the dose-limiting factor for its clinical use. A population pharmacokinetic–pharmacodynamic (PK–PD) model was introduced to predict the development o...

    Masato Fukae, Yoshimasa Shiraishi, Takeshi Hirota… in Cancer Chemotherapy and Pharmacology (2016)

  2. Article

    Open Access

    Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression

    Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, are promising therapies for advanced non-small c...

    Heyan Li, Koichi Takayama, Shuo Wang… in Cancer Chemotherapy and Pharmacology (2014)

    Download PDF (2896 KB) View Article

  3. No Access

    Article

    Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy

    Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that responds poorly to chemotherapy. Although treatment with pemetrexed in combination with cisplatin serves as first-line chemotherapy for MPM,...

    Gouji Toyokawa, Mitsuhiro Takenoyama… in International Journal of Clinical Oncology (2014)